Table 1.

Characteristics of studies included in the meta-analysis

Author, year	Year of study	Country	Disease stage	Operation type	Chemotherapy type	No. of VTEs	No. of participants	VTE diagnostic criterion	Study design
Fotopoulou et al., 2008 [27]	1995–2002	Germany	Advanced ovarian cancer	Debulking surgery	Adjuvant chemotherapy	76	2743	National Cancer Institute Common Toxicity Criteria	Case-control
Fotopoulou et al., 2009 [14]	1999–2005	Germany	Recurrent ovarian cancer	Radical surgery	Adjuvant chemotherapy	37	525	National Cancer Institute Common Toxicity Criteria	Case-control
Mereu et al., 2009 [28]	1990–2004	Italy	Ovarian cancer	Radical surgery	Adjuvant chemotherapy	16	203	Self-definition	Cross-sectional study
Guardiola et al., 2010 [29]	2004–2007	France	Recurrent ovarian cancer	Debulking surgery	Neoadjuvant chemotherapy	3	18	National Cancer Institute Common Toxicity Criteria	Cross-sectional study
Saadeh et al., 2013 [30]	2006–2010	Ireland	Ovarian cancer	Radical surgery	Neoadjuvant chemotherapy or adjuvant chemotherapy	31	227	Self-definition	Case-control
Pant et al., 2014 [31]	2008–2011	The USA	Advanced ovarian cancer	Radical surgery	Adjuvant chemotherapy	16	128	Self-definition	Case-control
Chavan et al., 2017 [15]	2012–2015	China	Ovarian cancer	Radical surgery	Neoadjuvant chemotherapy or adjuvant chemotherapy	20	147	Self-definition	Retrospective cohort
Greco et al., 2017 [32]	2009–2014	The USA	Advanced ovarian cancer	Debulking surgery	Neoadjuvant chemotherapy	12	111	Self-definition	Retrospective cohort
Kuk et al., 2017 [33]	NA	Poland	Advanced ovarian cancer	Debulking surgery	Adjuvant chemotherapy	5	57	Self-definition	Case-control
Zhang et al., 2018 [16]	2014–2017	China	Ovarian cancer	Debulking surgery	Neoadjuvant chemotherapy	35	370	Self-definition	Case-control
Salinaro et al., 2020 [17]	2000–2013	The USA	Ovarian cancer	Debulking surgery	Neoadjuvant chemotherapy	16	230	Self-definition	Retrospective cohort

VTE venous thromboembolism